Research Center of Neurology, Moscow, Russia.
Biomed Pharmacother. 2023 Dec;168:115723. doi: 10.1016/j.biopha.2023.115723. Epub 2023 Oct 18.
to assess executive network using resting-state fMRI and patterns of brain activation using task fMRI with a cognitive paradigm, against the background of taking the drug in comparison with placebo in patients with post-COVID asthenic syndrome.
The study employed a prospective, randomized, double-blind, placebo-controlled trial approach to assess the efficacy of utilizing functional MRI of the brain as a neuroprotective therapy for treating patients with chronic fatigue syndrome following COVID-19. The study included 30 patients matched by sex and age with post-COVID asthenic syndrome. All patients were examined with MFI-20, MoCA, FAS-10 scales, MRI using a Siemens MAGNETOM Prisma 3 T scanner before and after a course of therapy with coordination complex with succinate acid anion (CCSA) or placebo (15 patients each) using resting state fMRI and with cognitive paradigm.
The changes obtained as a result of the treatment of post-Covid asthenic syndrome demonstrated clinical superiority in the reduction of asthenic symptoms for the group of patients treated with CCSA (MFI-20 scores: -20·0 points in the CCSA group compared to -12 points in the placebo group, p = 0·043). The data obtained also correlate with the analysis of task fMRI and resting state fMRI may indicate an increase in the functional cognitive status after a course of therapy with CCSA. Clinically, this correlates with a statistically significant improvement in the MoCA score (2 points in the CCSA group compared to 1 point in the placebo group, p < 0·05).
the study demonstrates the potential effectiveness of CCSA therapy in relation to a wide range of symptoms (chronic fatigue syndrome/ asthenic syndrome and cognitive impairment) in patients with post-COVID syndrome. The first time demonstrated the effectiveness of neuroprotective therapy after post-COVID asthenic syndrome with the use of high-tech neuroimaging techniques.
评估使用静息态 fMRI 的执行网络和使用认知范式的任务 fMRI 的脑激活模式，背景是在患有 COVID-19 后虚弱综合征的患者中与安慰剂相比使用药物。
该研究采用前瞻性、随机、双盲、安慰剂对照试验方法，评估使用脑功能磁共振成像作为 COVID-19 后慢性疲劳综合征患者神经保护治疗的疗效。该研究纳入了 30 名性别和年龄匹配的 COVID-19 后虚弱综合征患者。所有患者均在接受治疗前后进行 MFI-20、MoCA、FAS-10 量表检查、使用西门子 MAGNETOM Prisma 3T 扫描仪进行 MRI，治疗方案为使用顺丁烯二酸阴离子配位复合物（CCSA）或安慰剂（每组 15 名患者），使用静息态 fMRI 和认知范式。
COVID-19 后虚弱综合征治疗后的变化显示，CCSA 治疗组虚弱症状减轻具有临床优势（CCSA 组 MFI-20 评分：-20·0 分，安慰剂组-12 分，p=0·043）。获得的数据还与任务 fMRI 的分析相关，静息态 fMRI 可能表明在接受 CCSA 治疗后功能认知状态的提高。临床上，这与 MoCA 评分的统计学显著改善相关（CCSA 组增加 2 分，安慰剂组增加 1 分，p<0·05）。
该研究表明 CCSA 治疗在 COVID-19 后综合征患者的广泛症状（慢性疲劳综合征/虚弱综合征和认知障碍）方面具有潜在的有效性。首次使用高科技神经影像学技术证明 COVID-19 后虚弱综合征后的神经保护治疗有效。
